Solid Lipid Nanoparticles for Potential Doxorubicin Delivery in Glioblastoma Treatment: Preliminary In Vitro Studies

The chemotherapeutic potential of doxorubicin-loaded PEG-b-PLGA nanopolymersomes in mouse breast cancer model

“…In recent years, numerous nanopharmaceuticals, including micelles, polymersomes, liposomes and solid lipid NPs, have been investigated to minimize the severe side effects of DOX and increase its antitumor and pharmacokinetic performance in vivo during cancer therapy [25][26][27][28].…”

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors

“…However, quick elimination of SLNs from the blood flow by reticule endothelial system (RES), encapsulation of hydrophilic and ionic anticancer drugs and controlling the rate and extent of drug release from SLNs are the major obstacles faced by SLNs that restrain them from becoming effective nanocarriers in anticancer drug delivery. All of these aspects of SLNs as anticancer drug carriers have been excellently reviewed by Wong et al 5 Few examples where SLN systems have been utilized for the delivery of anticancer drugs are docetaxel, 13 doxorubicin, 14 paclitaxel, 15 methotrexate 16 and 5-fluorouracil (5-FU). 17 …”

The “fate” of polymeric and lipid nanoparticles for brain delivery and targeting: Strategies and mechanism of blood–brain barrier crossing and trafficking into the central nervous system

“…In vitro permeation experiments through a primary human brain microvascular endothelial cell line (hCMEC/D3 cells monolayer) highlighted that loading the drug into the SLN increased DOX permeation by transcytosis across the BBB, without any toxic effect on BBB cells compared to the free drug. Furthermore, DOX-loaded SLN showed higher cytotoxic effects against glioblastoma cells cultured under the hCMEC/D3 monolayer compared to the free drug [42].…”

“…The increased efficacy of PTX-loaded SLN compared to the free drug could be probably due to an improved permeation through the endothelial cell monolayer related to the carrier ability to overcome the efflux by P-glycoprotein [41]. Recently, SLN prepared by fatty acid coacervation technique and containing behenic acid as lipid matrix, were studied for the delivery of doxorubicin (DOX) [42]. In vitro permeation experiments through a primary human brain microvascular endothelial cell line (hCMEC/D3 cells monolayer) highlighted that loading the drug into the SLN increased DOX permeation by transcytosis across the BBB, without any toxic effect on BBB cells compared to the free drug.…”